Eledon Pharmaceuticals (NASDAQ:ELDN – Get Free Report) will likely be releasing its earnings data before the market opens on Thursday, March 27th. Analysts expect Eledon Pharmaceuticals to post earnings of ($0.34) per share for the quarter.
Eledon Pharmaceuticals Stock Up 0.6 %
ELDN opened at $3.56 on Thursday. Eledon Pharmaceuticals has a twelve month low of $1.52 and a twelve month high of $5.54. The company has a fifty day moving average of $4.19 and a 200-day moving average of $3.85. The stock has a market cap of $212.67 million, a PE ratio of -1.77 and a beta of 0.80.
Analyst Upgrades and Downgrades
A number of research firms have commented on ELDN. Guggenheim began coverage on shares of Eledon Pharmaceuticals in a report on Tuesday, January 28th. They issued a “buy” rating and a $9.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Eledon Pharmaceuticals in a research note on Wednesday, November 20th.
About Eledon Pharmaceuticals
Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).
Featured Articles
- Five stocks we like better than Eledon Pharmaceuticals
- Pros And Cons Of Monthly Dividend Stocks
- What GTC 2025 Signals for NVIDIA Stock’s Next Big Move
- What is the S&P/TSX Index?
- Alphabet’s Officially In A Bear Market—Time To Buy?
- Overbought Stocks Explained: Should You Trade Them?
- D-Wave and Quantum Supremacy: Implications For Investors
Receive News & Ratings for Eledon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eledon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
